Preference, satisfaction and usability of subcutaneously administered methotrexate for rheumatoid arthritis or psoriatic arthritis: Results of a postmarketing surveillance study with a high-concentration formulation

Therapeutic Advances in Musculoskeletal Disease

Volumn 4, Issue 1, 2012, Pages 3-9

  Striesow, Frank ^a   Brandt, Andreas ^b  

^a Rheumatologische Schwerpunktpraxis   (Germany)

^b MEDAC GMBH   (Germany)

Author keywords

methotrexate; parenteral; postmarketing surveillance study; pre attached needle; prefilled syringe; psoriatic arthritis; rheumatoid arthritis; self administration; subcutaneous injection

Indexed keywords

METHOTREXATE; METOJECT; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; DRUG USE; FEMALE; HEALTH CARE AVAILABILITY; HUMAN; INDEPENDENCE; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; NURSE; OUTCOME ASSESSMENT; PATIENT PREFERENCE; PATIENT SATISFACTION; PHYSICIAN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; QUALITY OF LIFE; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; TREATMENT DURATION;

EID: 84857466526     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X11431004     Document Type: Article

References (12)

1. Ahern M.J. Chandran G. (1995) Category III symptom-modifying antirheumatic drugs. Clin Immunother 3: 196–217.
2. Balis F.M. Mirro J. Jr Reaman G.H. Evans W.E. McCully C. Doherty K.M. et al. (1988) Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol 6: 1882–1886.
3. Braun J. Kaestner P. Flaxenberg P. Wahrisch J. Hanke P. Demary W. et al. (2008) Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 58: 73–81.
4. Brooks P.J. Spruill W.J. Parish R.C. Birchmore D.A. (1990) Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. Arthritis Rheum 33: 91–94.
5. Müller-Ladner U. Rockwitz K. Brandt-Jürgens J. Haux R. Kastner P. Braun J. et al. (2010) Tolerability and patient/physician satisfaction with subcutaneously administered methotrexate provided in two formulations of different drug concentrations in patients with rheumatoid arthritis. Open Rheumatol J 4: 15–22.
6. Pavy S. Constantin A. Pham T. Gossec L. Maillefert J.F. Cantagrel A. et al. (2006) Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 73: 388–395.
7. Rutkowska-Sak L. Rell-Bakalarska M. Lisowska B. (2009) Oral vs. subcutaneous low-dose methotrexate treatment in reducing gastrointestinal side effects. Reumatologia 47: 207–211.
8. Sander O. Huebner G. Rau R. (1996) [Subcutaneous MTX - a reasonable addition of established modes of administration)]. Z Rheumatol 55(Suppl. 1): 111.
9. Sieper J. Braun J. (1996) [Therapy of rheumatoid arthritis]. Deut Med Wochenschr 121: 563–567.
10. Tarner I.H. Manger B. Fleck M. (2009) [Evidence-based recommendations of a national group of experts on the use of methotrexate in inflammatory rheumatic diseases]. Akt Rheumatol 34: 59–66.
11. Ward M.M. Fries J.F. (1998) Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981–1996. J Rheumatol 25: 408–416.
12. Zackheim H.S. (1992) Subcutaneous administration of methotrexate. J Am Acad Dermatol 26: 1008.